Physician profile
Paul Sliskovich
NPI 1245892934
$1,960.18
in general payments reported to CMS, 2019-2025
24 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.22 · 2022: $44.78 · 2023: $312 · 2024: $560 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.28 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $211.45 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $203.38 | 2024-2025 | |
| Pfizer INC. | $175.48 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.51 | 2024-2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $81.40 | 2023-2025 | Ztlido |
| Lilly USA, LLC | $74.42 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $62.51 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $50.64 | 2024-2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $49.52 | 2025 | Edarbi |
| Abbott Laboratories | $47.85 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $44.63 | 2022-2024 | Airsupra, Breztri |
| Shield Therapeutics INC | $43.92 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $43.03 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $39.32 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.75 | 2025 | Evkeeza |
| Sumitomo Pharma America, INC. | $29.05 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $24.62 | 2024 | Camzyos |
| Gilead Sciences, INC. | $23.91 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.66 | 2025 | Lifevest |
| Viiv Healthcare Company | $20.04 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.32 | 2024 | |
| Aurinia Pharma U.S., INC. | $18.27 | 2021 | |
| Esperion Therapeutics, INC. | $13.90 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sliskovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.